Literature DB >> 18036394

A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature.

Pavandeep Ghataorhe1, Allison W Kurian, Angela Pickart, Pamela Trapane, Jeffrey A Norton, Kerry Kingham, James M Ford.   

Abstract

High-penetrance autosomal dominant cancer susceptibility genes such as BRCA2 and MEN1 result in specific patterns of cancers in individuals who inherit germline mutations. Their incidence in the population is relatively low, however, and it is highly unusual to identify individuals with two or more inherited cancer gene mutations. We describe a family with multiple cases of MEN1-associated cancers as well as pancreatic adenocarcinoma, ovarian cancer, and male breast cancer, in which we identified germline mutations in both MEN1 and BRCA2. To our knowledge, this is the first report of a patient with both MEN1 and BRCA2 mutations and with a personal history of hyperparathyroidism and pancreatic neuroendocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036394     DOI: 10.1016/j.cancergencyto.2007.08.009

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Breast cancer associated with primary hyperparathyroidism: a nested case control study.

Authors:  Sophie Norenstedt; Fredrik Granath; Anders Ekbom; Jonas Bergh; Mats Lambe; Jan Adolfsson; Fredrik Warnberg; Jan Zedenius; Inga-Lena Nilsson
Journal:  Clin Epidemiol       Date:  2011-03-25       Impact factor: 4.790

2.  Multiple endocrine neoplasia type 1 associated with breast cancer: A case report and review of the literature.

Authors:  Young Ju Jeong; Hoon Kyu Oh; Jin Gu Bong
Journal:  Oncol Lett       Date:  2014-05-13       Impact factor: 2.967

3.  Co-occurrence of breast cancer and neuroendocrine tumours: New genetic insights beyond Multiple Endocrine Neoplasia syndromes.

Authors:  Vincent Larouche; Amit Akirov; Emily Thain; Raymond H Kim; Shereen Ezzat
Journal:  Endocrinol Diabetes Metab       Date:  2019-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.